GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Curis, Inc. (CRIS) [hlAlert]

Rating:
Buy CRIS
down 7.74 %

Curis, Inc. (CRIS) rated Buy by ThinkEquity

Posted on: Tuesday,  Nov 24, 2009  8:25 AM ET by ThinkEquity

ThinkEquity rated Buy Curis, Inc. (NASDAQ: CRIS) on 11/24/2009, when the stock price was $2.71. Since
then, Curis, Inc. has lost 7.75% as of 01/22/2016's recent price of $2.50.
If you would have followed this ThinkEquity's recommendation on CRIS, you would have lost 7.74% of your investment in 2250 days.

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.

Research is at the core of everything we do at ThinkEquity, and we're passionate about it. Employing a disciplined and rigorous process, we scrutinize the spectrum of forces at play in the growth sectors we cover. Starting with a top down analysis, we look closely at the megatrends and industry drivers that create opportunities for innovative companies. We then allocate our resources based on a long-range research roadmap that leads to deep domain expertise and a close working knowledge of the technologies, products, services and people that populate the growth sector landscape. In short, the sum result of the ThinkEquity research process is to identify and affiliate ourselves with the fastest growing private and public companies within our domain verticals.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/24/2009 8:25 AM Buy
None
2.71
as of 12/31/2009
1 Week down  -19.36 %
1 Month up  6.89 %
3 Months up  2.95 %
1 YTD up  2.95 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy